Dr. Craig Kenneth Deligdish, MD

Dr. Deligdish practices at Atlantis Diagnostics in Melbourne, Florida.

Dr. Deligdish's NPI, 1679564462, was assigned on November 2, 2005. Dr. Deligdish graduated from New York University School of Medicine in 1981. Dr. Deligdish holds Florida license ME53490.

Dr. Deligdish's primary practice is Atlantis Diagnostics, at 1344 S. Apollo Blvd., Melbourne, FL 32901. The practice phone is (321) 777-7888.

Dr. Deligdish's primary practice is Atlantis Diagnostics in Melbourne, Florida. Dr. Deligdish is also affiliated with Holmes Regional Medical Center. The medical group on file is OMNI Healthcare. Dmand AI also links Dr. Deligdish to 2 more hospitals, 1 physician office and 1 group practice or clinic, each named with a free account. Dr. Deligdish's employer is on file too: a breast imaging center.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Deligdish practices, 6 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Deligdish's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Deligdish is board certified in hematology by the American Board of Internal Medicine. Dmand AI has Dr. Deligdish's licenses on file in 2 states: Florida and Texas.

Dmand AI lists breast cancer, chronic anemia, deep vein thrombosis (DVT), lung cancer, lymphoma, multiple myeloma, prostate cancer and purpura and thrombocytopenia among the conditions Dr. Deligdish treats.

CMS data shows 30,010 Medicare services from Dr. Deligdish across 14 procedure codes in 2024, for 363 Medicare patients. Medicare paid $480,657 for them. Every service was in an office.

CMS counts 363 Medicare patients who saw Dr. Deligdish in 2024. The largest group is 65 to 74, with 160 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 9% are also on Medicaid. Their average risk score is 1.42, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Deligdish's median patient age at 71, with 56% women.

In 2024, Dr. Deligdish wrote 169 Medicare Part D claims for 59 patients. 73% of them were for generic drugs. CMS names the drug for 65 of them, across 4 drugs with 11 or more claims each, at $215,285 in total drug cost. In 2023, CMS named 142 claims across 6 drugs.

Dr. Deligdish accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 1 paper to Dr. Deligdish.

Dmand AI links Dr. Deligdish to 3 clinical trials. Conditions studied include Breast Neoplasms, Crohn Disease and Rectal Diseases. Eli Lilly and Company sponsors the most, 2. Open Payments lists research payments to Dr. Deligdish that name 2 trials.

CMS Open Payments shows 183 general payments to Dr. Deligdish from 49 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 87% of the total. Varian Medical Systems, Inc. paid the most, $531. It also lists 2 research payments totaling $1,646 in 2021, naming 2 clinical trials.

Dr. Deligdish graduated from New York University School of Medicine in 1981. Dr. Deligdish is a member of ASCO.

Dr. Deligdish is in network with 19 carriers, including Aetna, Elevance and Excellus BlueCross BlueShield. PPO plans come from the most carriers, 13. Check the plan with the practice before a visit.